139 related articles for article (PubMed ID: 35721759)
21. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Willis AI
Surg Oncol; 2019 Jun; 29():184-189. PubMed ID: 31196486
[TBL] [Abstract][Full Text] [Related]
22. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
23. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
24. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
25. Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer.
Al-Qurayshi Z; Bu Ali D; Srivastav S; Kandil E
Oncology; 2017; 93(2):122-126. PubMed ID: 28609768
[TBL] [Abstract][Full Text] [Related]
26. Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer: A retrospective study.
Wu C; Wang L; Chen W; Zou S; Yang A
Medicine (Baltimore); 2017 Mar; 96(9):e6202. PubMed ID: 28248875
[TBL] [Abstract][Full Text] [Related]
27. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
[TBL] [Abstract][Full Text] [Related]
28. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
29. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
30. Obesity and High Risk Pathological Features of Papillary Thyroid Carcinoma: A Retrospective Analysis of a University Hospital in Pakistan.
Zaman SU; Awan MS; Sulaiman MA
Gulf J Oncolog; 2018 May; 1(27):6-10. PubMed ID: 30145545
[TBL] [Abstract][Full Text] [Related]
31. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial.
Sawka AM; Straus S; Brierley JD; Tsang RW; Rotstein L; Rodin G; Gafni A; Ezzat S; Thabane L; Thorpe KE; Goldstein DP
Trials; 2010 Jul; 11():81. PubMed ID: 20659341
[TBL] [Abstract][Full Text] [Related]
32. Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients.
Elbasan O; Yavuz DG
Arch Endocrinol Metab; 2021 Nov; 65(4):455-461. PubMed ID: 33909380
[TBL] [Abstract][Full Text] [Related]
33. Blood prognostic predictors of treatment response for patients with papillary thyroid cancer.
Liu X; Huang Z; He X; Zheng X; Jia Q; Tan J; Fan Y; Lou C; Meng Z
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015713
[TBL] [Abstract][Full Text] [Related]
34. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies.
Xu L; Port M; Landi S; Gemignani F; Cipollini M; Elisei R; Goudeva L; Müller JA; Nerlich K; Pellegrini G; Reiners C; Romei C; Schwab R; Abend M; Sturgis EM
Thyroid; 2014 Jun; 24(6):966-74. PubMed ID: 24555500
[TBL] [Abstract][Full Text] [Related]
35. Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a).
Seo M; Kim YS; Lee JC; Han MW; Kim ES; Kim KB; Park SH
Clin Nucl Med; 2017 Nov; 42(11):842-846. PubMed ID: 28832376
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
[TBL] [Abstract][Full Text] [Related]
37. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
38. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
[TBL] [Abstract][Full Text] [Related]
39. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
[TBL] [Abstract][Full Text] [Related]
40. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
